Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial.

• Hepatic veno-occlusive disease is a leading cause of morbidity and mortality after haemopoietic stem-cell transplantation (HSCT). We aimed to assess whether defibrotide can reduce the incidence of veno-occlusive disease in this setting.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Pediatrik (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Pediatrics (hsv//eng)

Nyckelord

Adolescent

Bilirubin

blood

Child

Child

Preschool

Female

Fibrinolytic Agents

therapeutic use

Graft vs Host Disease

epidemiology

Hematopoietic Stem Cell Transplantation

adverse effects

Hepatic Veno-Occlusive Disease

drug therapy

epidemiology

prevention & control

Humans

Incidence

Infant

Infusions

Intravenous

Male

Multiple Organ Failure

epidemiology

Polydeoxyribonucleotides

therapeutic use

Renal Insufficiency

epidemiology

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)